067 CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics and clinical efficacy in post-myocardial infarction patients

Authors :: Guillaume Cayla
Olivier Barthelemy
Jean-Sébastien Hulot
Gilles Montalescot
Johanne Silvain
Frédérick Allanic
Anne Bellemain
Jean-Philippe Collet
Farzin Beygui
Source :: Archives of Cardiovascular Diseases Supplements. 4(1)
Publication Year :: 2012
Publisher :: Elsevier BV, 2012.

Subjects :: Oncology
medicine.medical_specialty
business.industry
Genetic variants
CYP2C19
Clopidogrel
PON1
Post myocardial infarction
Pharmacokinetics
Internal medicine
Pharmacodynamics
medicine
Clinical efficacy
business
Cardiology and Cardiovascular Medicine
medicine.drug

Full Text Access

Tools